BioCryst (BCRX) director awarded stock in lieu of cash retainer

Rhea-AI Filing Summary

McKee Amy E reported acquisition or exercise transactions in this Form 4 filing.

BIOCRYST PHARMACEUTICALS INC director Amy E. McKee reported receiving a grant of 631 shares of Common Stock on May 29, 2026 at a reference price of $8.91 per share. The shares were issued to her in lieu of 50% of a quarterly Board member cash retainer of $11,250. Following this compensation-related award, she directly holds 31,883 shares of the company’s Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McKee Amy E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	631	$8.91	$6K

Holdings After Transaction: Common Stock — 31,883 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 631 shares Reference price per share: $8.91 per share Quarterly Board retainer (cash reference): $11,250 +1 more

4 metrics

Shares granted 631 shares Common Stock grant to director on May 29, 2026

Reference price per share $8.91 per share Price reported for the 631-share award

Quarterly Board retainer (cash reference) $11,250 50% replaced by Common Stock issuance

Shares held after transaction 31,883 shares Director Amy McKee’s direct holdings post-award

Key Terms

Common Stock, Board Member retainer, grant/award acquisition, Form 4

4 terms

Common Stock financial

"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Board Member retainer financial

"in lieu of 50% of the quarterly cash Board Member retainer of $11,250"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKee Amy E

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		A		631(1)	A	$8.91	31,883	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.

	/s/ Alane P. Barnes, by power of attorney	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BioCryst (BCRX) director Amy McKee report?

Director Amy E. McKee reported receiving 631 shares of BioCryst Common Stock as a grant on May 29, 2026. This was a compensation-related share award rather than an open-market purchase or sale.

At what price were Amy McKee’s BioCryst shares recorded in the Form 4?

The 631 shares granted to Amy McKee were recorded at a price of $8.91 per share. This figure reflects the reference price used in the Form 4, not an open-market trade execution price.

Why did Amy McKee receive BioCryst shares instead of cash?

Amy McKee received the shares in lieu of 50% of her quarterly Board member cash retainer of $11,250. The company issued Common Stock as part of her compensation rather than paying the full retainer in cash.

How many BioCryst shares does Amy McKee hold after this grant?

After receiving the 631-share grant, Amy McKee directly holds 31,883 shares of BioCryst Common Stock. This total reflects her direct ownership position following the reported compensation-related award.

Was Amy McKee’s BioCryst transaction a market buy or sell?

The transaction was reported as a grant or award acquisition, not a market buy or sell. Shares were issued to Amy McKee as part of her Board compensation package, replacing half of a scheduled cash retainer payment.